JP2020512822A5 - - Google Patents

Download PDF

Info

Publication number
JP2020512822A5
JP2020512822A5 JP2019555010A JP2019555010A JP2020512822A5 JP 2020512822 A5 JP2020512822 A5 JP 2020512822A5 JP 2019555010 A JP2019555010 A JP 2019555010A JP 2019555010 A JP2019555010 A JP 2019555010A JP 2020512822 A5 JP2020512822 A5 JP 2020512822A5
Authority
JP
Japan
Prior art keywords
nucleic acid
isolated nucleic
seq
composition
cep290
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019555010A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512822A (ja
JP7307480B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/026230 external-priority patent/WO2018187552A1/en
Publication of JP2020512822A publication Critical patent/JP2020512822A/ja
Publication of JP2020512822A5 publication Critical patent/JP2020512822A5/ja
Priority to JP2023020149A priority Critical patent/JP7535332B2/ja
Application granted granted Critical
Publication of JP7307480B2 publication Critical patent/JP7307480B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019555010A 2017-04-05 2018-04-05 ミニ遺伝子療法 Active JP7307480B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023020149A JP7535332B2 (ja) 2017-04-05 2023-02-13 ミニ遺伝子療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762481727P 2017-04-05 2017-04-05
US62/481,727 2017-04-05
PCT/US2018/026230 WO2018187552A1 (en) 2017-04-05 2018-04-05 Minigene therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023020149A Division JP7535332B2 (ja) 2017-04-05 2023-02-13 ミニ遺伝子療法

Publications (3)

Publication Number Publication Date
JP2020512822A JP2020512822A (ja) 2020-04-30
JP2020512822A5 true JP2020512822A5 (enExample) 2021-05-13
JP7307480B2 JP7307480B2 (ja) 2023-07-12

Family

ID=63712901

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019555010A Active JP7307480B2 (ja) 2017-04-05 2018-04-05 ミニ遺伝子療法
JP2023020149A Active JP7535332B2 (ja) 2017-04-05 2023-02-13 ミニ遺伝子療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023020149A Active JP7535332B2 (ja) 2017-04-05 2023-02-13 ミニ遺伝子療法

Country Status (7)

Country Link
US (2) US11739346B2 (enExample)
EP (1) EP3606544B1 (enExample)
JP (2) JP7307480B2 (enExample)
CN (2) CN110709095B (enExample)
AU (2) AU2018248304C1 (enExample)
CA (1) CA3059112A1 (enExample)
WO (1) WO2018187552A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087580A1 (en) * 2015-11-16 2017-05-26 Synlogic, Inc. Bacteria engineered to reduce hyperphenylalaninemia
JP7307480B2 (ja) * 2017-04-05 2023-07-12 ユニバーシティ オブ マサチューセッツ ミニ遺伝子療法
EP3956453A4 (en) 2019-04-19 2023-02-22 University of Massachusetts GENE THERAPIES FOR USHER SYNDROME (USH1B)
US20220202959A1 (en) * 2019-04-19 2022-06-30 University Of Massachusetts Gene therapies for usher syndrome (ush2a)
EP3972610B1 (en) * 2019-05-20 2025-09-03 University of Massachusetts Minigene therapy
GB2606844B (en) 2019-09-18 2025-08-06 Aldevron Llc Synthetic DNA vectors and methods of use
WO2022023284A1 (en) 2020-07-27 2022-02-03 Anjarium Biosciences Ag Compositions of dna molecules, methods of making therefor, and methods of use thereof
CN112062827B (zh) * 2020-09-16 2022-10-21 中国人民解放军军事科学院军事医学研究院 Cep55蛋白在调控纤毛去组装和制备纤毛相关疾病模型中的应用
EP4255457A4 (en) * 2020-12-03 2025-05-21 University of Massachusetts DEVELOPMENT OF NEW GENE THERAPEUTIC AGENTS FOR FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
EP4288553A4 (en) * 2021-02-02 2025-06-25 University of Massachusetts INVERTED TERMINAL REPEAT SEQUENCES OF AAV SEROTYPES 8 AND RH.39 IN GENE THERAPY VECTORS

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
JP2001500015A (ja) 1996-09-06 2001-01-09 トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア T7ポリメラーゼを利用する組換えアデノ随伴ウイルスの誘導可能な製造方法
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
SG10202108118RA (en) 2001-11-13 2021-08-30 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
WO2009121536A1 (en) 2008-04-02 2009-10-08 Fondazione Telethon Method of treating genetic disorders
US10266845B2 (en) 2013-02-08 2019-04-23 The Trustees Of The University Of Pennsylvania Enhanced AAV-mediated gene transfer for retinal therapies
EP2986635B1 (en) * 2013-04-18 2018-10-03 Fondazione Telethon Effective delivery of large genes by dual aav vectors
WO2015009575A1 (en) * 2013-07-16 2015-01-22 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of disorders related to cep290
EP3030665B9 (en) 2013-08-05 2023-10-04 Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum Recombinant aav-crumbs homologue composition and methods for treating lca-8 and progressive rp
CA2948728A1 (en) 2014-03-10 2015-09-17 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
US10351844B2 (en) 2014-08-27 2019-07-16 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Methods and compositions for treating leber congenital amaurosis
AU2016355343C1 (en) 2015-11-19 2024-10-03 Lloyd G. Mitchell Compositions and methods for correction of heritable ocular disease
EP3393522B1 (en) 2015-12-22 2021-07-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Improved hybrid dual recombinant aav vector systems for gene therapy
US20170348387A1 (en) * 2016-02-29 2017-12-07 The Trustees Of The University Of Pennsylvania Aav-mediated gene therapy for nphp5 lca-ciliopathy
CA3032822A1 (en) 2016-08-02 2018-02-08 Editas Medicine, Inc. Compositions and methods for treating cep290 associated disease
JP7307480B2 (ja) 2017-04-05 2023-07-12 ユニバーシティ オブ マサチューセッツ ミニ遺伝子療法
EP3645052A4 (en) 2017-06-30 2021-07-28 Regents of the University of California ADENO-ASSOCIATED VIRUS VIRIONS WITH ASSOCIATED CAPSIDE VARIANTS AND METHODS OF USE
KR102763312B1 (ko) 2017-10-20 2025-02-07 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 치료적으로 유효한 양의 재조합 aav9- 유도 벡터의 망막하 전달을 포함하는 대상체의 원추 광수용체 내 관심의 폴리뉴클레오티드를 발현하는 방법
EP3972610B1 (en) 2019-05-20 2025-09-03 University of Massachusetts Minigene therapy

Similar Documents

Publication Publication Date Title
US20230414724A1 (en) Treatment of hyperbilirubinemia
JP6453307B2 (ja) デュアルaavベクターによる大型遺伝子の効果的送達
IL278213B1 (en) A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd)
JP2023088902A5 (enExample)
CN103562396A (zh) 用于无脉络膜的基因疗法的aav载体
KR20160033217A (ko) 변종 aav 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도
JP2023535956A5 (enExample)
JP2024099770A5 (enExample)
JP2022529782A5 (enExample)
JP2019524090A5 (enExample)
KR20250102136A (ko) 중추 신경계에서의 유전자 발현을 위한 핵산 조절 요소 및 사용 방법
KR102855673B1 (ko) 폐 세포 특이적 유전자 전달이 가능한 아데노부속바이러스 벡터
US20220389450A1 (en) Vector system
US12480098B1 (en) Adeno-associated virus variant
HK40053434B (en) Treatment of hyperbilirubinemia
CN121127272A (zh) 用于治疗眼底黄色斑点症的双aav载体
HK40053434A (en) Treatment of hyperbilirubinemia
HK40010983A (en) Nucleic acids comprising a modified intron for use in the treatment of hyperbilirubinemia
HK40010983B (en) Nucleic acids comprising a modified intron for use in the treatment of hyperbilirubinemia
HK1234780B (en) Treatment of hyperbilirubinemia
HK1234780A1 (en) Treatment of hyperbilirubinemia